Chin N X, Gu J W, Neu H C
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.
Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):79-83. doi: 10.1016/0732-8893(91)90093-u.
Ceftibuten is a new beta-lactamase-stable 3-aminothiazolyl cephalosporin that lacks activity against staphylococci and group-B streptococci. We determined the effect of the combination of ceftibuten with SCH 29482, an orally absorbed penem. The combination of the two agents was additive for 25% or indifferent for 57% of the Gram-positive species, Haemophilus, and Moraxella tested with a mean fractional inhibitory concentration (FIC) index of 0.75. The combination of ceftibuten and SCH 29482 was also indifferent for Bacteroides fragilis and other Bacteroides species, all of which were inhibited by less than or equal to micrograms/ml of SCH 29482. Antagonism of the combination was found for 80% of Serratia marcescens and for 30% of Citrobacter freundii and Enterobacter cloacae. Overall, the combination of ceftibuten and SCH 29482 at concentrations that can be achieved in serum after ingestion of 400 and 50 micrograms/ml, respectively, provided antibacterial activity against most Gram-positive aerobic and anaerobic species that cause upper respiratory, intraabdominal, and urinary infections.
头孢布烯是一种新型的对β-内酰胺酶稳定的3-氨基噻唑基头孢菌素，对葡萄球菌和B组链球菌无活性。我们测定了头孢布烯与一种口服吸收的青霉烯类药物SCH 29482联合使用的效果。对于所测试的25%的革兰氏阳性菌、嗜血杆菌属和莫拉菌属，这两种药物的联合作用为相加作用，57%为无关作用，平均部分抑菌浓度（FIC）指数为0.75。头孢布烯与SCH 29482的联合对脆弱拟杆菌和其他拟杆菌属也无相互作用，所有这些菌都能被≤微克/毫升的SCH 29482抑制。发现该联合用药对80%的粘质沙雷氏菌以及30%的弗氏柠檬酸杆菌和阴沟肠杆菌有拮抗作用。总体而言，分别摄入400和50微克/毫升后血清中所能达到的浓度的头孢布烯与SCH 29482联合用药，对大多数引起上呼吸道、腹腔内和泌尿系统感染的革兰氏阳性需氧菌和厌氧菌具有抗菌活性。
